Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysisResearch in context

Summary: Background: With increasing recognition of the value of incorporating prognostic markers into amyotrophic lateral sclerosis (ALS) trial design and analysis plans, there is a pressing need to understand which among the prevailing clinical and biochemical markers have real value, and how the...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Michael Benatar, Eric A. Macklin, Andrea Malaspina, Mary-Louise Rogers, Eran Hornstein, Vittoria Lombardi, Danielle Renfrey, Stephanie Shepheard, Iddo Magen, Yahel Cohen, Volkan Granit, Jeffrey M. Statland, Jeannine M. Heckmann, Rosa Rademakers, Caroline A. McHutchison, Leonard Petrucelli, Corey T. McMillan, Joanne Wuu, Lauren Elman, John Ravits, Jonathan Katz, Jaya Trivedi, Andrea Swenson, Ted M. Burns, James Caress, Carlayne Jackson, Samuel Maiser, Erik P. Pioro, Yuen So
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2024-10-01
Cyfres:	EBioMedicine
Pynciau:	Prognostic biomarkers Context-of-use ALS clinical trials Neurofilament
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S2352396424003591
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!